NancySarahShulmanMD

Infectious Disease • San Mateo, CA

HIV/AIDS Medicine

Attending Physician

Join to view full profile

Dr. Shulman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shulman's full profile

Already have an account?

Office
Edison Clinic
222 W. 39th Ave
San Mateo, CA 94403

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 1996 - 2000
University of ChicagoResidency, Internal Medicine, 1991 - 1995
University of Kansas School of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1995 - 2025
IL State Medical License 1991 - 1996

Clinical Trials

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure Start of enrollment: 2008 Sep 01
Completed
Phase 4

Publications & Presentations

PubMed

5 citations
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage
Andrew H. Talal, Emily O. Dumas, Barbara M. Bauer, Richard M Rejman, Andrew J. Ocque
The Journal of Infectious Diseases. 2018-01-17
209 citations
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
Paul J. Pockros, K. Rajender Reddy, Parvez S. Mantry, Eric Cohen, Michael J. Bennett
Gastroenterology. 2016-06-01
100 citations
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
Jürgen K. Rockstroh, Karine Lacombe, Rolando M Viani, Chloe Orkin, David L. Wyles
Clinical Infectious Diseases. 2018-09-14

Journal Articles

inform \
shulman, lancet

Press Mentions

Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial EnrollmentJune 3rd, 2023

Grant Support

Feasibility Of CCR5 Inhibitors In Preventing Maternal To Infant SIV TransmissionNational Center For Research Resources2009–2010
Feasibility Of CCR5 Inhibitors In Preventing Maternal To Infant SIV TransmissionNational Institute Of Allergy And Infectious Diseases2008–2009
Non-Nucleoside Reverse Transcriptive HypersensitivityNational Institute Of Allergy And Infectious Diseases2002–2006